Adaptimmune receives Nasdaq delisting notice for MVLS below $35M; 180-day cure period

Adaptimmune Therapeutics PLC

Nasdaq notified Adaptimmune on Sept 11, 2025 that MVLS was below $35M minimum for 32 consecutive business days.
Company also fails alternative continued listing standards: equity below $2.5M or net income below $500K.
Has 180 calendar days (until March 10, 2026) to regain MVLS compliance for at least 10 consecutive business days.
No immediate effect on ADAP ADS trading; failure to comply may result in delisting with appeal option.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.